133 related articles for article (PubMed ID: 34686504)
1. miR-145-5p Modulates Gefitinib Resistance by Targeting NRAS and MEST in Non-Small Cell Lung Cancer.
Yu C; Li B; Wang J; Zhang Z; Li S; Lei S; Wang Q
Ann Clin Lab Sci; 2021 Sep; 51(5):625-637. PubMed ID: 34686504
[TBL] [Abstract][Full Text] [Related]
2. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
3. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
[TBL] [Abstract][Full Text] [Related]
4. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
Gong J; He L; Ma J; Zhang J; Wang L; Wang J
J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
[TBL] [Abstract][Full Text] [Related]
5. miR-365a-5p suppresses gefitinib resistance in non-small-cell lung cancer through targeting PELI3.
Li F; Li H; Li S; Lv B; Shi J; Yan H; Zhang H; He Y
Pharmacogenomics; 2020 Jul; 21(11):771-783. PubMed ID: 32635799
[No Abstract] [Full Text] [Related]
6. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
[TBL] [Abstract][Full Text] [Related]
8. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
Fan D; Yang Y; Zhang W
BMC Pulm Med; 2022 Jan; 22(1):27. PubMed ID: 34996416
[TBL] [Abstract][Full Text] [Related]
9. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
11. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
Liu B; Wang R; Liu H
Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
[TBL] [Abstract][Full Text] [Related]
12. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
13. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
14. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
[TBL] [Abstract][Full Text] [Related]
15. Circ_SETD3 regulates gefitinib sensitivity and tumor progression by miR-873-5p-dependent regulation of APPBP2 in non-small cell lung cancer.
Sheng J; Liu L; Dong T; Wu X
J Chemother; 2022 Oct; 34(6):401-413. PubMed ID: 34861803
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rh2 attenuates the progression of non-small cell lung cancer by sponging miR-28-5p/STK4 axis and inactivating Wnt/β-catenin signaling.
Ma J; Zhao D; Yu D; Song W; Yang X; Yin H
Cancer Med; 2023 Jun; 12(11):12653-12667. PubMed ID: 37081781
[TBL] [Abstract][Full Text] [Related]
17. Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib.
Wang C; Ding S; Sun B; Shen L; Xiao L; Han Z; Huang H
Pharmacol Res; 2020 Nov; 161():105110. PubMed ID: 32755614
[TBL] [Abstract][Full Text] [Related]
18. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.
Sun Y; Chen C; Zhang P; Xie H; Hou L; Hui Z; Xu Y; Du Q; Zhou X; Su B; Gao W
Sci Rep; 2014 Oct; 4():6527. PubMed ID: 25284075
[TBL] [Abstract][Full Text] [Related]
19. The novel miR-873-5p-YWHAE-PI3K/AKT axis is involved in non-small cell lung cancer progression and chemoresistance by mediating autophagy.
Li Z; Liu J; Wang P; Zhang B; He G; Yang L
Funct Integr Genomics; 2024 Feb; 24(2):33. PubMed ID: 38363382
[TBL] [Abstract][Full Text] [Related]
20. Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway.
Niu R; Li D; Chen J; Zhao W
Cell Cycle; 2022 Jan; 21(1):86-100. PubMed ID: 34919024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]